Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs
Simone Ferretti,Chiara Mercinelli,Laura Marandino,Giulio Litterio,Michele Marchioni,Luigi Schips
DOI: https://doi.org/10.2147/RRU.S385257
2023-06-26
Research and Reports in Urology
Abstract:Simone Ferretti, 1, &ast Chiara Mercinelli, 2, &ast Laura Marandino, 2 Giulio Litterio, 1 Michele Marchioni, 1 Luigi Schips 1 1 Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti, Urology Unit, Chieti, Italy; 2 Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy &astThese authors contributed equally to this work Correspondence: Michele Marchioni, Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti, Urology Unit, Chieti, Italy, Tel +393296544866, Fax +390871357756, Email The therapeutic landscape of metastatic hormone sensitive and metastatic castration-resistant prostate cancer (mCRPC) is rapidly changing. We reviewed the current treatment options for mCRPC, with insights on new available therapeutic strategies. Chemotherapy with docetaxel or cabazitaxel (for patients progressing on docetaxel), as well as treatment with androgen receptor axis targeted therapies, and Radium-223 are well-established treatment options for patients with mCRPC. The advent of theragnostic in prostate cancer established Lutetium-177 (177Lu)–PSMA-617 as a new standard of care for PSMA-positive mCRPC previously treated with ARAT and taxane-based chemotherapy. Olaparib, a poly-ADP-ribose polymerase (PARP) inhibitor, is approved for selected patients with mCRPC progressed on ARATs and in combination with abiraterone acetate as first-line treatment for mCRPC. Immunotherapy showed limited efficacy in unselected patients with mCRPC and novel immunotherapy strategies need to be explored. The search for biomarkers is a growing field of interest in mCRPC, and predictive biomarkers are needed to support the choice of treatment and the development of tailored strategies. Keywords: metastatic castration resistant prostate cancer, chemotherapy, androgen-receptors axis targeted therapies, PARP inhibitors, theragnostic, predictive biomarkers Prostate cancer (PCa) is the first malignant tumor in male population by incidence and second by death, with 27% of new diagnoses of all incident cancer cases in men every year and 11% of all cancer-related deaths. 1 Localized PCa has survival rates >90% at 5 years, which decrease to 31% in advanced and metastatic settings. 2 Androgen deprivation therapy (ADT) is a backbone therapy for metastatic hormone-sensitive prostate cancer (mHSPC). In years, many other compounds were introduced in the treatment of mHSPC in combination with ADT: chemotherapy (docetaxel), androgen receptor axis targeted therapies (ARATs) such as abiraterone acetate, enzalutamide, apalutamide, and darolutamide. 3 However, most of the patients develop metastatic castration-resistant prostate cancer (mCRPC), a condition that carries a worse prognosis. CRPC is defined as biochemical progression while on ADT, defined by three consecutive rises in PSA at least one week apart, or as radiological progression with castration serum testosterone levels, below 50 ng/dL. 4 In the last years, the landscape of mCRPC treatment has deeply changed, with the introduction of several new compounds. The choice of the best option as first-line therapy [Table 1] and what to use in further lines [Table 2] depends on several factors, such as the treatment previously received, clinical conditions of the patient, metastatic sites and other tumour characteristics. For this reason, the correct sequence treatment is not well defined. Table 1 Characteristics of Main Studies First- and Second-Line Treatment of mCRPC Table 2 Characteristics of Main Studies of Other-Lines of mCRPC We aimed to perform a review of the literature on mCRPC treatment landscape, with insights into currently available drugs and innovative treatment options. Taxanes – docetaxel and cabazitaxel – are the most active chemotherapy drugs currently used for the treatment of mCRPC. Docetaxel is a semisynthetic taxane with a high cytotoxic effect that inhibits microtubular depolymerization, leading to cell arrest in the G(2)M phase of the cell cycle, promoting a cascade of events that ultimately leads to apoptotic cell death. 23 Two historical trials support the efficacy of docetaxel in mCRPC. SWOG 99–16 is a randomized Phase III trial that included 674 patients randomized to receive docetaxel and estramustine (D/E arm) or mitoxantrone and prednisone (M/P arm). 5 The results showed a higher median overall survival (mOS) in patients treated with docetaxel and estramustine compared to those treated with mitoxantrone and prednisone (17.5 vs 15.6 months; HR for death 0.80). 5 The median progression-free survival (mPFS) was -Abstract Truncated-
English Else